MDPV: Difference between revisions

>David Hedlund
'''Monkey Dust'''
>David Hedlund
restored '''Monkey Dust'''
 
(3 intermediate revisions by 2 users not shown)
Line 3: Line 3:
{{SubstanceBox/MDPV}}
{{SubstanceBox/MDPV}}


'''3,4-Methylenedioxypyrovalerone''' (also known as '''MDPV''', '''Bath Salts''', '''Monkey Dust''', among many others) is a novel lesser-known [[psychoactive class::stimulant]] substance of the [[substituted cathinone|cathinone]] and [[substituted pyrrolidine|pyrrolidine]] classes. It is known to be one of the most powerful and potent stimulants. MDPV is thought to act primarily as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI).
'''3,4-Methylenedioxypyrovalerone''' (also known as '''MDPV''', and '''Monkey Dust'''<ref>{{cite news |title=Monkey dust "epidemic" causing drug users to experience violent hallucinations |url=https://www.newsweek.com/what-monkey-dust-bath-salt-mpvd-drug-causing-epidemic-violent-hallucinations-1068295 |access-date=17 August 2018 |work=Newsweek |date=10 August 2018 |language=en}}</ref>) is a novel lesser-known [[psychoactive class::stimulant]] substance of the [[substituted cathinone|cathinone]] and [[substituted pyrrolidine|pyrrolidine]] classes. It is known to be one of the most powerful and potent stimulants. MDPV is thought to act primarily as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI).


MDPV was first developed in the 1960s by a team at Boehringer Ingelheim.<ref name="KoppePatent">{{Citation | vauthors=((Koppe, H.)), ((Ludwig, G.)), ((Zeile, K.)) | title=1-(3’,4’-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1) | url=https://patents.google.com/patent/US3478050/en}}</ref> It was claimed to have potential to be an alternative for racemic amphetamine and, despite showing some desirable qualities such as reduced toxicity as compared to amphetamine, was chosen to not be developed as a medicinal drug.<ref>MDPV Summary | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref>
MDPV was first developed in the 1960s by a team at Boehringer Ingelheim.<ref name="KoppePatent">{{Citation | vauthors=((Koppe, H.)), ((Ludwig, G.)), ((Zeile, K.)) | title=1-(3’,4’-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1) | url=https://patents.google.com/patent/US3478050/en}}</ref> It was claimed to have potential to be an alternative for racemic amphetamine and, despite showing some desirable qualities such as reduced toxicity as compared to amphetamine, was chosen to not be developed as a medicinal drug.<ref>MDPV Summary | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref>
Line 173: Line 173:
*[https://erowid.org/chemicals/mdpv/mdpv.shtml MDPV (Erowid Vault)]
*[https://erowid.org/chemicals/mdpv/mdpv.shtml MDPV (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=2143 MDPV (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=2143 MDPV (Isomer Design)]
*[https://drugs-forum.com/wiki/MDPV MDPV (Drugs-Forum)]


===Discussion===
===Discussion===
Line 188: Line 189:
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Proofread]]
[[Category:Proofread]]
{{#set:Featured=true}}
Retrieved from "http://psy.st/wiki/MDPV"